Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Awaiting development
Reference number: GID-TA11087
Expected publication date: TBC
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia have been revised. It is anticipated that the appraisal will begin in mid-May 2024 when we will write to you about how you can get involved.